Table 1. Baseline (enrollment) clinical characteristics and laboratory testing results of the hospitalized study population Uganda (N = 351).
| Characteristic | Total N = 351 (% or IQR) | Alive N = 202 (% or IQR) | Dead N = 75 (% or IQR) | Unknown status N = 74 (% or IQR) |
| Female | 226 (64.4) | 123(60.9) | 53(70.7) | 50(67.6) |
| Median age in years (SD) | 31(27,38) | 32(7.9) | 30(8.8) | 31(7.7) |
| Median Karnofsky score (SD) | 60 (5.9)) | 60(5.6) | 60(6.2) | 60(6.1)) |
| 80–100 | 113 (32.2 | 71(35.2) | 15(20) | 27(36.5) |
| 50–70 | 238 (67.8) | 131(64.9) | 60(80) | 47(63.5 |
| Median CD4 (IQR) cells/mm3+ | 57 (14,179) | 73(18,200) | 22(8,72) | 90.5(18,195) |
| CD4 counts (cells/mm3) <50 | 167 (47.6) | 89(44.1) | 47(62.7) | 31(41.9) |
| CD4 counts (cells/mm3) 50–99 | 42 (12.0) | 23(11.4) | 11(14.7) | 8(10.8) |
| CD4 counts (cells/mm3) 100–199 | 62 (17.7) | 37(18.3) | 7(9.3) | 18(24.3) |
| CD4 counts (cells/mm3) ≥200 | 75 (21.4) | 50(24.8) | 8(10.7) | 17(22.9) |
| On antiretroviral therapy at enrollment | 132 (37.6) | 81(40.1) | 26(34.7) | 25(33.8) |
| On cotrimoxazole prophylaxis at enrollment | 299 (85.2) | 176(87.1) | 67(89.3) | 56(75.7) |
| Cough for more than 14 days | 220(62.7) | 124(61.4) | 49(65.3) | 47(63.5) |
| Fevers-within past 4 weeks | 330 (94.1) | 189(93.6) | 71(94.7) | 157(77.7) |
| Night sweats-within past 4 weeks | 274 (78.1) | 157(77.7) | 56(74.7) | 61(82.4) |
| Weight loss-within past 4 weeks | 339 (96.6) | 192(95.1) | 74(98.6) | 73(98.7) |
| Chest X-ray compatible with TB | 207(59.0) | 118(58.4) | 43(57.3) | 46(62.1) |
| TB treatment ever prescribed | 50 (14.3) | 37(18.3) | 6(8) | 7(9.5) |
| Respiratory specimen smear positive for acid fast bacilli | 45 (12.8) | 27(13.3) | 12(16.0) | 6(8.1) |
| Respiratory specimen culture positive for Mtb* | 133 (37.9) | 72(35.6) | 29(38.7) | 32(43.2) |
| Respiratory specimen culture positive for Mtb but all smears negative | 53 (15.1) | 30(14.8) | 11(14.7) | 12(16.2) |
| Blood culture positive for Mtb** | 69 (19.7) | 37(18.3) | 19(25.3) | 13(17.6) |
| Blood culture positive for non-tuberculous mycobacteria | 0 | 0 | 0 | 0 |
| Blood culture positive for Mtb but no respiratory culture positive for Mtb | 12 (3.4) | 9(4.4) | 3(4.0) | 0 |
| Any culture positive for Mtb | 145 (41.3) | 81(40.1) | 32(42.7) | 32(43.2) |
| Lateral LAM flow positive ≥2+ | 90 (25.6) | 45(22.2) | 28(37.3) | 17(23.0) |
| Lateral LAM flow any band positive | 134 (38.2) | 74(36.6) | 38(50.7) | 22(29.7) |
| Cryptococccal antigen test positive | 25 (7.1) | 14(6.9) | 10(13.3) | 1(1.4) |
| LAM or CRAG antigen test positive | 151 (43) | 83 (41.1) | 45 (60.0) | 23 (31.1) |
| Xpert MTB/RIF test positive | 93 (26.5) | 54(26.7) | 23(30.7) | 16(21.6) |
Number alive = 202 patients, number dead at 2 months = 75 patients, number unknown status at 2 months = 74 patients, CI = confidence intervals, N = number, IQR = interquartile range, SD = standard deviation, TB = tuberculosis, Mtb = Mycobacterium tuberculosis, LAM = lipoarabinomannan, CRAG = cryptococcal antigen.
*2 results missing.
**7 results missing.
+3
of the patients confirmed alive and 2 of the dead patients at 2 months had CD4 count missing.